Clinical trial for Polycystic Ovarian Syndrome (PCOS)
Official title Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS
ClinicalTrials.gov ID: NCT06793904
What this study is testing
What is Aromatase inhibitor Letrozole?
Aromatase inhibitor Letrozole is an investigational medicine, being studied as a potential treatment for polycystic ovarian syndrome (pcos).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares HOMA1‑IR and HOMA2‑IR scores to determine which better predicts ovulation in women with polycystic ovarian syndrome.
- Who it's for
- Women with PCOS who are trying to become pregnant and are attending the fertility clinic at Kasr Alainy Hospital.
- What's involved
- All participants will have blood tests to calculate HOMA1‑IR and HOMA2‑IR, then take Letrozole 2.5 mg twice daily from day 3 to day 7 of their cycle. Ultrasound scans will monitor follicle growth, and additional FSH medication may be added if needed.
- Time commitment
- The study lasts one menstrual cycle, with daily medication for five days and several ultrasound visits until a dominant follicle reaches 18‑22 mm.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 35, women only
You may be able to join if
- Age 18-35 years
- duration of infertility 1-4 years
- PCOS
You likely can't join if
- women with other causes of infertility (tubal factor assessed by laparoscopy or hysterosalpingogram, uterine cavity abnormality assessed by...
- endometriosis,
- ovarian cysts,
- endocrinological abnormalities (Diabetes mellitus, hypothalamic, pituitary or thyroid disorders, or hyperprolactinemia),
- women with history of poor ovarian response or ovarian hyperstimulation
- women with chronic diseases, chromosomal, autoimmune or coagulation defects, abnormal leucocytic count or other inflammatory markers
See the full eligibility criteria
- Age 18-35 years
- duration of infertility 1-4 years
- PCOS
- women with other causes of infertility (tubal factor assessed by laparoscopy or hysterosalpingogram, uterine cavity abnormality assessed by ultrasound or hysteroscopy or male factor assessed by seme analysis),
- endometriosis,
- ovarian cysts,
- endocrinological abnormalities (Diabetes mellitus, hypothalamic, pituitary or thyroid disorders, or hyperprolactinemia),
- women with history of poor ovarian response or ovarian hyperstimulation
- women with chronic diseases, chromosomal, autoimmune or coagulation defects, abnormal leucocytic count or other inflammatory markers
- Women with contraindications to pregnancy.
The study team makes the final eligibility decision.
Where it is enrolling
- Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Cairo, Egypt. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.